近日，华纳药厂发布2025年度业绩快报，公司实现营业总收入15.16亿元，同比增长7.26%；归母净利润2.41亿元，同 比增长46.95%。 （华纳药厂公告） 报告期内，公司营业收入增长主要系公司制剂产品、原料药及中间体产品销售收入增长以及技术服务收入增长共同所 致；归属于母公司所有者的净利润增加主要是受投资收益影响；归属于母公司所有者的扣除非经常性损益的净利润下 滑主要是因为计提股权激励费用影响，剔除股权激励费用影响后，归属于母公司所有者的扣除非经常性损益的净利润 为 1.82 亿元，较上年同期增加 31.57%。 ...

单位：万元 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以湖南华纳大药 厂股份有限公司（以下简称"公司"）2025年年度报告为准，提请投资者注意投资风险。 一、2025年度主要财务数据和指标 （二）主要财务数据和指标增减变动幅度达30%以上的主要原因 报告期内，公司营业利润同比增长51.53%、利润总额同比增长51.88%、归属于母公司所有者的净利润 同比增长46.95%、基本每股收益同比增长47.20%，主要系上海致根医药科技有限公司增资扩股引入战 略投资者并调整董事会结构，公司不再对其进行控制、不再纳入公司合并报表范围，公司持有的剩余股 权按照公允价值计算并确认的投资收益所致。报告期末公司股本同比增长40.00%，是因为2025年5月公 司以资本公积金向全体股东每10股转增4股，转增后公司股本数量由93,800,000股增加至131,320,000股。 三、风险提示 ■ 注：1、2025年5月，公司以资本公积金向全体股东每10股转增4股 ...

北京商报讯（记者 丁宁）2月13日晚间，华纳药厂（688799）发布2025年业绩快报显示，公司2025年度 实现营业收入15.16亿元，同比增长7.26%；归属净利润为2.41亿元，同比增长46.95%。 华纳药厂表示，报告期内，公司营业收入增长主要系公司制剂产品、原料药及中间体产品销售收入增长 以及技术服务收入增长共同所致；归属净利润增加主要是受投资收益影响。 ...

Group 1 - RuiLian New Materials reported a total operating revenue of 1.677 billion yuan for 2025, an increase of 14.95% year-on-year, with a net profit of 311 million yuan, up 23.48% year-on-year [1] - China Shenhua's subsidiary, Guoneng Qingyuan Power, successfully put its fourth generator unit into commercial operation, expected to provide approximately 20 billion kWh of clean energy annually [2] - Qijiang Airlines announced a 6.04% year-on-year decline in passenger turnover for January 2026, with a passenger load factor of 84.03%, up 1.61% year-on-year [3] Group 2 - QiZheng Tibetan Medicine reported a total operating revenue of 2.416 billion yuan for 2025, a year-on-year increase of 3.34%, with a net profit of 646 million yuan, up 10.98% year-on-year [5] - QiaoYin Co. announced the termination of its artificial intelligence industry headquarters project due to changes in investment cooperation conditions [6] - New Point Software plans to use 90.81 million yuan of surplus raised funds for new projects, including AI-driven software development [7] Group 3 - High Measurement Co. announced plans for major shareholders and executives to reduce their holdings by up to 3.19% of the company's shares [8] - SAIC Group's subsidiary plans to establish a private equity fund with an initial scale of 2.5 billion yuan, focusing on solid-state batteries and chip localization [9] - Tianqi Lithium announced the resignation of its deputy general manager due to personal career planning [10] Group 4 - ZhongKong Technology reported a total operating revenue of 8.051 billion yuan for 2025, a decrease of 11.90%, with a net profit of 450 million yuan, down 59.70% year-on-year [11] - Spring Airlines reported a 6.28% year-on-year increase in total passenger volume for January 2026, with a total available ton-kilometers of 57,008.37 [12] - Qifan Cable's controlling shareholder reduced its stake by 3% through various trading methods [13] Group 5 - China Chemical signed contracts worth a total of 36.925 billion yuan in January 2026, with significant contracts exceeding 5 billion yuan totaling 11.371 billion yuan [19] - SaiTuo Bio received a CEP certificate for its raw material drug Betamethasone, which is used to treat allergies and autoimmune inflammation [20] - Giant Star Agriculture reported a sales revenue of 649 million yuan from commodity fat pigs in January 2026, with a sales volume of 404,400 pigs [23] Group 6 - Qinglong Pipe Industry's subsidiary won a 146 million yuan pipeline project [24] - Changshan Pharmaceutical announced that some of its products are expected to be selected for national centralized procurement [26] - Yangdian Technology completed the transfer of 12.96% of its shares through an agreement [27] Group 7 - Deepin Technology's investment fund introduced new limited partners and adjusted the capital contributions of some partners [28] - Qingyun Technology plans to pledge 25% of its shares for a loan application of up to 30 million yuan [29] - LaiMei Pharmaceutical reported a 57.20% year-on-year decline in net profit for 2025 [30] Group 8 - YouLiDe reported a 16.88% year-on-year decline in net profit for 2025, with total operating revenue of 1.221 billion yuan, up 7.99% [31] - Warner Pharmaceutical reported a net profit of 241 million yuan for 2025, an increase of 46.95% year-on-year [32] - LianRui New Materials reported a net profit of 293 million yuan for 2025, an increase of 16.42% year-on-year [33] Group 9 - HuaQin Technology expects a 24.28% year-on-year decrease in net profit for 2025, with projected revenue of 1.251 billion yuan, up 9.83% [34] - QiPai Technology's shareholder subscribed for 6.3 million shares, accounting for 5.49% of the total share capital [35] - Qilin Security's shareholders completed their planned share reductions without exceeding the original plan [36] Group 10 - Dameng Data announced the lifting of the detention of its senior vice president, allowing him to resume his duties [37] - Haiyou Engineering won a contract for the "NFPS COMP5" project worth approximately 4 billion USD, with the company's share exceeding 800 million USD [38] - Yatai Group plans to sell 20.81% of its shares in Northeast Securities, pending confirmation of financial statements [39]

（文章来源：证券日报） 证券日报网讯 2月13日，华纳药厂发布公告称，公司2025年度实现营业收入151，559.43万元，同比增长 7.26%；归属于母公司所有者的净利润24，146.73万元，同比增长46.95%。 ...

华纳药厂(688799.SH)披露2025年度业绩快报，2025年度实现营业收入15.16亿元，同比增长7.26%;归属 于母公司所有者的净利润2.41亿元，同比增长46.95%。 报告期内，公司营业收入增长主要系公司制剂产品、原料药及中间体产品销售收入增长以及技术服务收 入增长共同所致;归属于母公司所有者的净利润增加主要是受投资收益影响;归属于母公司所有者的扣除 非经常性损益的净利润下滑主要是因为计提股权激励费用影响，剔除股权激励费用影响后，归属于母公 司所有者的扣除非经常性损益的净利润为1.82亿元，较上年同期增加31.57%。 ...

报告期内，公司营业收入增长主要系公司制剂产品、原料药及中间体产品销售收入增长以及技术服务收 入增长共同所致;归属于母公司所有者的净利润增加主要是受投资收益影响;归属于母公司所有者的扣除 非经常性损益的净利润下滑主要是因为计提股权激励费用影响，剔除股权激励费用影响后，归属于母公 司所有者的扣除非经常性损益的净利润为1.82亿元，较上年同期增加31.57%。 智通财经APP讯，华纳药厂(688799.SH)披露2025年度业绩快报，2025年度实现营业收入15.16亿元，同 比增长7.26%;归属于母公司所有者的净利润2.41亿元，同比增长46.95%。 ...

Core Viewpoint - Warner Pharmaceuticals (688799.SH) reported a preliminary performance summary for the fiscal year 2025, indicating a revenue increase and significant growth in net profit, driven by various product sales and investment income [1] Financial Performance - The company achieved an operating revenue of 1.516 billion yuan, representing a year-on-year growth of 7.26% [1] - The net profit attributable to the parent company was 241 million yuan, showing a year-on-year increase of 46.95% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 130 million yuan, reflecting a year-on-year decline of 6.01% [1] Asset and Equity Growth - At the end of the reporting period, the total assets of the company reached 3.053 billion yuan, marking a year-on-year growth of 24.11% [1] - The equity attributable to the parent company was 2.046 billion yuan, which is a year-on-year increase of 13.44% [1] Revenue Drivers - The growth in operating revenue was primarily due to increased sales of formulation products, raw materials, intermediates, and technical service income [1] - The increase in net profit attributable to the parent company was mainly influenced by investment income [1] - The decline in net profit after deducting non-recurring gains and losses was attributed to the accrual of equity incentive expenses; excluding this impact, the adjusted net profit was 182 million yuan, which is a 31.57% increase compared to the same period last year [1]

证券代码：688799 证券简称：华纳药厂 公告编号：2026-005 2、以上财务数据及指标以合并报表数据填制，但未经审计，最终结果以公司 2025 年年 度报告为准。 3、以上增减变动幅度数据如有尾差，系四舍五入所致。 二、经营业绩和财务状况情况说明 湖南华纳大药厂股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计， 具体数据以湖南华纳大药厂股份有限公司（以下简称"公司"）2025年年度报告 为准，提请投资者注意投资风险。 | | 单位：万元 | | | | --- | --- | --- | --- | | 项目 | 本报告期 增减变动幅度（％） | 上年同期 | | | 营业总收入 | 151,559.43 7.26 | 141,294.92 | | | 营业利润 | 24,513.09 51.53 | 16,176.58 | | | 利润总额 | 24,554.73 51.88 | 16,167.63 | ...

南财智讯2月13日电，华纳药厂发布2025年度业绩快报，报告期内公司实现营业收入15.16亿元，同比增 长7.26%；归属于上市公司股东的净利润2.41亿元，同比增长46.95%；基本每股收益1.84元，同比增长 47.20%。 ...